Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T04:35:24Z', 'timestamp': 1711600524335}, 'posted': {'date-parts': [[2022, 6, 8]]}, 'group-title': 'Pharmacology and Therapeutics', 'reference-count': 58, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2022, 6, 8]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>We investigated Favipiravir (FPV) efficacy in mild ' 'cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical ' 'condition, and risk of COVID-19 pneumonia development. PCR-confirmed SARS-CoV-2-infected ' 'patients without pneumonia were enrolled (2:1) within 10 days of symptomatic onset into FPV ' 'and control arms. The former received 1800 mg FPV twice-daily (BID) on Day 1 and 800 mg BID ' '5-14 days thereafter until negative viral detection, while the latter received supportive ' 'care only. The primary endpoint was time to clinical improvement, which was defined by a ' 'reduced National Early Warning Score (NEWS) or score of ≤1. 62 patients (41 female) comprised ' 'the FPV arm (median age: 32 years, median BMI: 22 kg/m²) and 31 patients (19 female) ' 'comprised the control arm (median age: 28 years, median BMI: 22 kg/m². The median time to ' 'sustained clinical improvement by NEWS was 2 vs 14 days for FPV and control arms respectively ' '(adjusted hazard ratio (aHR) of 2.77, 95% CI 1.57-4.88, <jats:italic>P</jats:italic> ' '&lt;0.001). The FPV arm also had significantly higher likelihoods of clinical improvement ' 'within 14 days after enrolment by NEWS (79% vs 32% respectively, <jats:italic>P</jats:italic> ' '&lt;0.001), particularly female patients (aOR 6.35, 95% CI 1.49-27.07, ' '<jats:italic>P</jats:italic> &lt;0.001). 8 (12.9%) and 7 (22.6%) patients in FPV and control ' 'arms developed mild pneumonia at a median (range) 6.5 (1-13) and 7 (1-13) days after ' 'treatment, respectively (<jats:italic>P</jats:italic> = 0.316); all recovered well without ' 'complications. We can conclude that early treatment of FPV in symptomatic COVID-19 patients ' 'without pneumonia was associated with faster clinical improvement.</jats:p>', 'DOI': '10.1101/2022.06.06.22275902', 'type': 'posted-content', 'created': {'date-parts': [[2022, 6, 8]], 'date-time': '2022-06-08T15:00:11Z', 'timestamp': 1654700411000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, ' 'Open-Labelled, Randomized Control Study', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-1486-5550', 'authenticated-orcid': False, 'given': 'Rujipas', 'family': 'Sirijatuphat', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2583-9390', 'authenticated-orcid': False, 'given': 'Weerawat', 'family': 'Manosuthi', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4785-2716', 'authenticated-orcid': False, 'given': 'Suvimol', 'family': 'Niyomnaitham', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrew', 'family': 'Owen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Katherine K.', 'family': 'Copeland', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3811-0267', 'authenticated-orcid': False, 'given': 'Lantharita', 'family': 'Charoenpong', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-1150-2597', 'authenticated-orcid': False, 'given': 'Manoch', 'family': 'Rattanasompattikul', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7555-1056', 'authenticated-orcid': False, 'given': 'Surakameth', 'family': 'Mahasirimongkol', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0140-4600', 'authenticated-orcid': False, 'given': 'Kulkanya', 'family': 'Chokephaibulkit', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2022061002451014000_2022.06.06.22275902v1.1', 'unstructured': 'Organization WH. WHO Coronavirus (COVID-19) Dashboard 2022. Available ' 'from: https://covid19.who.int/'}, { 'issue': '2', 'key': '2022061002451014000_2022.06.06.22275902v1.2', 'doi-asserted-by': 'crossref', 'first-page': '78', 'DOI': '10.35772/ghm.2020.01031', 'article-title': 'Coronavirus disease 2019 (COVID-19): research progress and clinical ' 'practice', 'volume': '2', 'year': '2020', 'journal-title': 'Glob Health Med'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jinf.2021.01.015'}, { 'issue': '10', 'key': '2022061002451014000_2022.06.06.22275902v1.4', 'first-page': '1192', 'article-title': 'Experimental Treatment with Favipiravir for COVID-19: An Open-Label ' 'Control Study', 'volume': '6', 'year': '2020', 'journal-title': 'Engineering (Beijing)'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pntd.0008806'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.6', 'doi-asserted-by': 'crossref', 'first-page': '501', 'DOI': '10.1016/j.ijid.2020.10.069', 'article-title': 'Role of favipiravir in the treatment of COVID-19', 'volume': '102', 'year': '2021', 'journal-title': 'Int J Infect Dis'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0249090'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Doi Y , Hibino M , Hase R , et al. A Prospective, Randomized, Open-Label ' 'Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients ' 'with COVID-19. Antimicrob Agents Chemother. 2020 Nov 17;64(12).', 'DOI': '10.1128/AAC.01897-20'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.11.142'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41591-021-01283-z'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.11', 'unstructured': 'Eroglu E , Toprak C. Overview of favipiravir and remdesivir treatment ' 'for COVID-19. International Journal of Pharmaceutical Sciences and ' 'Research. 2021:1950–1957.'}, { 'issue': '5', 'key': '2022061002451014000_2022.06.06.22275902v1.12', 'doi-asserted-by': 'crossref', 'first-page': '228', 'DOI': '10.1007/s40495-020-00226-5', 'article-title': 'Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 ' 'Pandemic: a Recent Update', 'volume': '6', 'year': '2020', 'journal-title': 'Curr Pharmacol Rep'}, { 'issue': '1', 'key': '2022061002451014000_2022.06.06.22275902v1.13', 'doi-asserted-by': 'crossref', 'first-page': '489', 'DOI': '10.1186/s12879-021-06164-x', 'article-title': 'Favipiravir for the treatment of patients with COVID-19: a systematic ' 'review and meta-analysis', 'volume': '21', 'year': '2021', 'journal-title': 'BMC Infect Dis'}, { 'issue': '3', 'key': '2022061002451014000_2022.06.06.22275902v1.14', 'first-page': '87', 'article-title': 'Evaluating the Treatment with Favipiravir in Patients Infected by ' 'COVID-19', 'volume': '2', 'year': '2020', 'journal-title': 'A Systematic Review and Meta-analysis International Journal of ' 'Scientific Research in Dental and Medical Sciences'}, { 'issue': '4', 'key': '2022061002451014000_2022.06.06.22275902v1.15', 'doi-asserted-by': 'crossref', 'first-page': '919', 'DOI': '10.1007/s42399-021-00824-4', 'article-title': 'Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for ' 'COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment', 'volume': '3', 'year': '2021', 'journal-title': 'SN Compr Clin Med'}, { 'issue': '3', 'key': '2022061002451014000_2022.06.06.22275902v1.16', 'doi-asserted-by': 'crossref', 'first-page': '1403', 'DOI': '10.1002/jmv.26397', 'article-title': 'Comparative analysis of antiviral efficacy of FDA-approved drugs ' 'against SARS-CoV-2 in human lung cells', 'volume': '93', 'year': '2021', 'journal-title': 'J Med Virol'}, { 'issue': '6', 'key': '2022061002451014000_2022.06.06.22275902v1.17', 'doi-asserted-by': 'crossref', 'first-page': '939', 'DOI': '10.1002/cbic.202000595', 'article-title': 'Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic ' 'Options', 'volume': '22', 'year': '2021', 'journal-title': 'Chembiochem'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.18', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12985-020-01412-z'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116846'}, { 'issue': '6', 'key': '2022061002451014000_2022.06.06.22275902v1.20', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients', 'volume': '386', 'year': '2022', 'journal-title': 'New England Journal of Medicine'}, { 'issue': '13', 'key': '2022061002451014000_2022.06.06.22275902v1.21', 'doi-asserted-by': 'crossref', 'first-page': 'e32', 'DOI': '10.1056/NEJMc2201612', 'article-title': 'Molnupiravir for Covid-19 in Nonhospitalized Patients', 'volume': '386', 'year': '2022', 'journal-title': 'New England Journal of Medicine'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.22', 'doi-asserted-by': 'crossref', 'unstructured': 'Brophy JM . Molnupiravir’s authorisation was premature. British Medical ' 'Journal Publishing Group; 2022.', 'DOI': '10.1136/bmj.o443'}, { 'issue': '2', 'key': '2022061002451014000_2022.06.06.22275902v1.23', 'first-page': '143', 'article-title': 'Favipiravir in COVID-19', 'volume': '19', 'year': '2020', 'journal-title': 'International Journal of Progressive Sciences and Technologies'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.24', 'doi-asserted-by': 'publisher', 'DOI': '10.2183/pjab.93.027'}, { 'issue': '4', 'key': '2022061002451014000_2022.06.06.22275902v1.25', 'doi-asserted-by': 'crossref', 'first-page': '370', 'DOI': '10.1016/j.mjafi.2020.08.004', 'article-title': 'Favipiravir: A new and emerging antiviral option in COVID-19', 'volume': '76', 'year': '2020', 'journal-title': 'Med J Armed Forces India'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.26', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'}, { 'issue': '3', 'key': '2022061002451014000_2022.06.06.22275902v1.27', 'doi-asserted-by': 'crossref', 'first-page': '531', 'DOI': '10.1093/cid/ciaa1176', 'article-title': 'AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease ' '2019 (COVID-19): Interim Results of a Phase II/III Multicenter ' 'Randomized Clinical Trial', 'volume': '73', 'year': '2021', 'journal-title': 'Clin Infect Dis'}, { 'issue': '2', 'key': '2022061002451014000_2022.06.06.22275902v1.28', 'doi-asserted-by': 'crossref', 'first-page': '33', 'DOI': '10.14740/jem645', 'article-title': 'Favipiravir: A Possible Pharmaceutical Treatment for COVID-19', 'volume': '10', 'year': '2020', 'journal-title': 'Journal of Endocrinology & Metabolism'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.29', 'doi-asserted-by': 'crossref', 'unstructured': 'Holubar M , Subramanian A , Purington N , et al. Favipiravir for ' 'treatment of outpatients with asymptomatic or uncomplicated COVID-19: a ' 'double-blind randomized, placebo-controlled, phase 2 trial. Clin Infect ' 'Dis. 2022 Apr 21.', 'DOI': '10.1093/cid/ciac312'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.30', 'doi-asserted-by': 'crossref', 'unstructured': 'Shinada K , Sato T , Moriyama S , et al. Longitudinal Analysis of ' 'Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after ' 'Treatment with or without Favipiravir. Viruses. 2022 Mar 24;14(4).', 'DOI': '10.3390/v14040670'}, { 'issue': '12', 'key': '2022061002451014000_2022.06.06.22275902v1.31', 'doi-asserted-by': 'crossref', 'first-page': '2575', 'DOI': '10.1007/s10096-021-04307-1', 'article-title': 'Effectiveness of favipiravir in COVID-19: a live systematic review', 'volume': '40', 'year': '2021', 'journal-title': 'Eur J Clin Microbiol Infect Dis'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.32', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m2980'}, { 'issue': '1', 'key': '2022061002451014000_2022.06.06.22275902v1.33', 'doi-asserted-by': 'crossref', 'first-page': '11022', 'DOI': '10.1038/s41598-021-90551-6', 'article-title': 'The efficacy and safety of Favipiravir in treatment of COVID-19: a ' 'systematic review and meta-analysis of clinical trials', 'volume': '11', 'year': '2021', 'journal-title': 'Sci Rep'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.34', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2055-6640(20)30016-9'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.35', 'unstructured': 'Fujifilm Toyama Chemical Co. L. Notice of The New Drug Application ' 'Approval of “AVIGAN® Tablet 200mg” in Japan for the Anti-influenza Virus ' 'Drug 2014. Available from: ' 'https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.36', 'doi-asserted-by': 'crossref', 'unstructured': 'Prasithsirikul W , Pongpirul K , Sakornsakolpat P , et al. Adjunctive ' 'favipiravir for severe COVID-19: a retrospective observational study of ' 'the first 41 patients in Thailand. Asian Biomedicine. 2020;14(3).', 'DOI': '10.1515/abm-2020-0016'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.37', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pntd.0001342'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.38', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2014.02.014'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.39', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.00356-07'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.40', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciw571'}, { 'issue': '6', 'key': '2022061002451014000_2022.06.06.22275902v1.41', 'doi-asserted-by': 'crossref', 'first-page': '534', 'DOI': '10.1097/JCMA.0000000000000318', 'article-title': 'Potential therapeutic agents against COVID-19: What we know so far', 'volume': '83', 'year': '2020', 'journal-title': 'J Chin Med Assoc'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.42', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.02346-12'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.43', 'doi-asserted-by': 'crossref', 'unstructured': 'Sheahan TP , Sims AC , Zhou S , et al. An orally bioavailable ' 'broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial ' 'cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 ' 'Apr 29;12(541).', 'DOI': '10.1126/scitranslmed.abb5883'}, { 'issue': '4', 'key': '2022061002451014000_2022.06.06.22275902v1.44', 'first-page': '572', 'article-title': 'Assessement of outcomes following implementation of antiviral treatment ' 'guidelines for COVID-19 during the first wave in Thailand', 'volume': '52', 'year': '2021', 'journal-title': 'Southeast Asian Journal of Tropical Medicine and Public Health'}, { 'issue': '7', 'key': '2022061002451014000_2022.06.06.22275902v1.45', 'doi-asserted-by': 'crossref', 'first-page': '1051', 'DOI': '10.1016/j.jiac.2021.04.013', 'article-title': 'Early favipiravir treatment was associated with early defervescence in ' 'non-severe COVID-19 patients', 'volume': '27', 'year': '2021', 'journal-title': 'Journal of Infection and Chemotherapy'}, { 'issue': '3', 'key': '2022061002451014000_2022.06.06.22275902v1.46', 'doi-asserted-by': 'crossref', 'first-page': '166', 'DOI': '10.1055/a-1296-7935', 'article-title': 'Favipiravir and COVID-19: A Simplified Summary', 'volume': '71', 'year': '2021', 'journal-title': 'Drug Res (Stuttg)'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.47', 'doi-asserted-by': 'crossref', 'unstructured': 'Srinivas P , Sacha G , Koval C. Antivirals for COVID-19. Cleaveland ' 'Clinical Journal of Medicine. 2020.', 'DOI': '10.3949/ccjm.87a.ccc030'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.48', 'unstructured': 'Medical Research Foundation T. Thai Clinical Trials Registry 2021. ' 'Available from: https://thaiclinicaltrials.org/'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.49', 'unstructured': 'Health Do. National Early Warning Score: National Clinical Guideline No. ' '1 2013.'}, { 'issue': '5', 'key': '2022061002451014000_2022.06.06.22275902v1.50', 'doi-asserted-by': 'crossref', 'first-page': '414', 'DOI': '10.4103/ijp.ijp_998_20', 'article-title': 'Systematic review and meta-analysis of effectiveness and safety of ' 'favipiravir in the management of novel coronavirus (COVID-19) patients', 'volume': '52', 'year': '2020', 'journal-title': 'Indian J Pharmacol'}, { 'issue': '5', 'key': '2022061002451014000_2022.06.06.22275902v1.51', 'doi-asserted-by': 'crossref', 'first-page': '416', 'DOI': '10.7883/yoken.JJID.2020.827', 'article-title': 'Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients ' 'Receiving Favipiravir', 'volume': '74', 'year': '2021', 'journal-title': 'Jpn J Infect Dis'}, { 'issue': '4', 'key': '2022061002451014000_2022.06.06.22275902v1.52', 'doi-asserted-by': 'crossref', 'first-page': '555', 'DOI': '10.1080/14787210.2022.2012155', 'article-title': 'Evaluation of favipiravir in the treatment of COVID-19 based on the ' 'real-world', 'volume': '20', 'year': '2022', 'journal-title': 'Expert Rev Anti Infect Ther'}, { 'issue': '628', 'key': '2022061002451014000_2022.06.06.22275902v1.53', 'doi-asserted-by': 'crossref', 'first-page': 'eabl7430', 'DOI': '10.1126/scitranslmed.abl7430', 'article-title': 'A phase 2a clinical trial of molnupiravir in patients with COVID-19 ' 'shows accelerated SARS-CoV-2 RNA clearance and elimination of ' 'infectious virus', 'volume': '14', 'year': '2022', 'journal-title': 'Sci Transl Med'}, { 'issue': '2', 'key': '2022061002451014000_2022.06.06.22275902v1.54', 'doi-asserted-by': 'crossref', 'first-page': '209', 'DOI': '10.1016/S1473-3099(21)00485-0', 'article-title': 'Remdesivir plus standard of care versus standard of care alone for the ' 'treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a ' 'phase 3, randomised, controlled, open-label trial', 'volume': '22', 'year': '2022', 'journal-title': 'Lancet Infect Dis'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.55', 'unstructured': 'Chuah CH , Chow TS , Hor CP , et al. Efficacy of Early Treatment with ' 'Favipiravir on Disease Progression among High Risk COVID-19 Patients: A ' 'Randomized, Open-Label Clinical Trial. Clin Infect Dis. 2021 Nov 19.'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.56', 'unstructured': '35 generic manufacturers sign agreements with MPP to produce low-cost, ' 'generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in ' 'combination with ritonavir for supply in 95 low-and middle-income ' 'countries [Internet]. Medicines Patent Pool; 2022. Available from: ' 'https://medicinespatentpool.org/news-publications-post/35-generic-manufacturers-sign-agreements-with-mpp-to-produce-low-cost-generic-versions-of-pfizers-oral-covid-19-treatment-nirmatrelvir-in-combination-with-ritonavir-for-supply-in-95-low-and'}, { 'key': '2022061002451014000_2022.06.06.22275902v1.57', 'unstructured': '27 generic manufacturers sign agreements with MPP to produce low-cost ' 'versions of COVID-19 antiviral medication molnupiravir for supply in 105 ' 'low-and-middle-income countries [Internet]. Medicines Patent Pool; 2022. ' 'Available from: ' 'https://medicinespatentpool.org/news-publications-post/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir'}, { 'issue': '8', 'key': '2022061002451014000_2022.06.06.22275902v1.58', 'doi-asserted-by': 'crossref', 'first-page': '2121', 'DOI': '10.1093/jac/dkab135', 'article-title': 'Pharmacokinetic modelling to estimate intracellular favipiravir ' 'ribofuranosyl-5’-triphosphate exposure to support posology for ' 'SARS-CoV-2', 'volume': '76', 'year': '2021', 'journal-title': 'J Antimicrob Chemother'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2022.06.06.22275902', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 6, 10]], 'date-time': '2022-06-10T09:46:15Z', 'timestamp': 1654854375000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2022.06.06.22275902'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 6, 8]]}, 'references-count': 58, 'URL': 'http://dx.doi.org/10.1101/2022.06.06.22275902', 'relation': {}, 'published': {'date-parts': [[2022, 6, 8]]}, 'subtype': 'preprint'}